Using antiviral treatment to prevent liver cancer in patients with HBV and HIV.
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma
This study is looking at how well antiviral treatments can help prevent liver cancer in people who have both hepatitis B and HIV in Uganda and Senegal, and it aims to improve local research to better understand these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10903773 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of antiviral treatments in preventing hepatocellular carcinoma (HCC) among patients co-infected with hepatitis B virus (HBV) and HIV in sub-Saharan Africa. The study aims to form a large cohort of patients from Uganda and Senegal, where HCC is prevalent and often diagnosed at advanced stages. By initiating guideline-appropriate antiviral therapy, the research seeks to interrupt or reverse the impact of chronic infections that lead to liver cancer. The project also focuses on enhancing local research capabilities and infrastructure to support ongoing investigations into these diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with chronic HBV and HIV, particularly those residing in sub-Saharan Africa.
Not a fit: Patients who do not have HBV or HIV, or those who are not located in the targeted regions of Africa, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of liver cancer in patients with HBV and HIV, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results in using antiviral treatments to manage chronic infections and reduce cancer risk, indicating potential success for this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Kirk, Gregory D — Johns Hopkins University
- Study coordinator: Kirk, Gregory D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.